Business Context and Reporting Period
This Form 8-K is filed by Aikido Pharma Inc. (not Dominari Holdings Inc.) on April 28, 2020. The report addresses a regulatory notice regarding the continued listing of the Company's common stock on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price performance:
- Minimum Bid Price Requirement: $1.00 per share.
- Observed Closing Bid Price: Below $1.00 during the period from March 16, 2020, to April 27, 2020.
Material Changes
The Company received a staff deficiency notice from Nasdaq stating it failed to comply with Listing Rule 5550(a)(2) due to the sustained low bid price. This represents a material change in the Company's listing status, triggering a compliance period.
Guidance, Outlook, and Risks
Compliance Timeline:
- Compliance Period: 180 calendar days, ending December 28, 2020.
- Requirement to Regain Compliance: The closing bid price must meet or exceed $1.00 per share for a minimum of 10 consecutive business days prior to the deadline.
- Market Conditions: Nasdaq has tolled compliance periods for bid price and market value requirements through June 30, 2020, due to extraordinary market conditions.
Investor Verification Checklist
- Verify the current trading price of AIKI to assess proximity to the $1.00 threshold.
- Monitor the Company's stock price for 10 consecutive business days to track progress toward compliance.
- Review subsequent filings for any announcements regarding reverse stock splits or other capital structure changes intended to address the bid price deficiency.
- Confirm the Company's status regarding the June 30, 2020 tolling period expiration.